Company Provides Revised Timing on Interim Celgosivir Viral Kinetics
VANCOUVER and SAN DIEGO, Oct. 31 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC:
MGIFF), a clinical-stage developer of drugs for infectious diseases will
present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
being held at the New York Palace Hotel in New York, NY on November 5-7, 2007.
Jim DeMesa, M.D., President & CEO is scheduled to present on Monday, November
5 at 4:45 p.m. EST in the Holmes I room.
As part of an overall corporate update, Dr. DeMesa will highlight the
- Omigard(TM) - a partnered Phase III product candidate for the
prevention of catheter-related infections
- Celgosivir - a Phase II product candidate for treating chronic
hepatitis C virus infections
- CLS001 - recent Phase II results from our partnered topical treatment
Additionally, interim 4-week data expected in October from a Phase II
viral kinetics combination study of celgosivir in patients with chronic HCV
(genotype 1) infection are delayed due to sample analysis not being completed
at a contract research organization. Results will be reported when available,
which is now anticipated to be in November.
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II and
preclinical), the prevention of catheter-related infections (Phase III) and
the treatment of dermatological diseases (Phase II). MIGENIX is headquartered
in Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at www.migenix.com.
James M. DeMesa, M.D.
President & CEO
This news release contains forward-looking statements within the meaning
of the United States Private Securities Litigation Reform Act of 1995, and
forward-looking information within the meaning of applicable securities laws
in Canada, (collectively referred to as "forward-looking statements").
Statements, other than statements of historical fact, are forward-looking
statements. By their nature, forward-looking statements involve numerous
assumptions, known and unknown risks and uncertainties, both general and
specific, that contribute to the possibility that the predictions, forecasts,
projections and other things contemplated by the forward-looking statements
will not occur.
Although our management believes that the expectations represented by
such forward-looking statements are reasonable, there is significant risk that
the forward-looking statements may not be achieved, and the underlying
assumptions thereto will not prove to be accurate. Forward-looking statements
in this news release include, but are not limited to, statements concerning
our expectations for: interim 4-week data from a Phase II viral kinetics
combination study of celgosivir now being anticipated in November.
With respect to the forward-looking statements contained in this news
release, we have made numerous assumptions regarding, among other things: the
contract organization's ability to complete the sample analysis and the
completion of the interim 4-week data analysis being in November 2007.
Actual results or events could differ materially from the plans,
intentions and expectations expressed or implied in any forward-looking
statements, including the underlying assumptions thereto, as a result of
numerous risks, uncertainties and other factors including: dependence on
corporate collaborations; uncertainties related to early stage of technology
and product development; and potential delays. Certain of these factors and
other factors are described in detail in the Company's Annual Information Form
and Annual Report on Form 20-F for and other filings with the Canadian
securities regulatory authorities and the U.S. Securities & Exchange
Forward-looking statements are based on our current expectations and
MIGENIX assumes no obligations to update such information to reflect later
events or developments.
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, email@example.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com